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doi:10.1016/j.jtcvs.2007.11.010Objective: Inappropriate multiorgan endothelial-leukocyte activation is major causa-
tive factor in organ dysfunction after cardiac surgery. We investigated in vitro, mech-
anism and magnitude of attenuation of the pathogenic response through pretreatment
with an u-3 fatty acid infusion.
Methods: Perioperative saphenous endothelial cell monolayers were pretreated and
then stimulated with perioperative inflammatory mediators. Endothelial production
of interleukin 6, interleukin 8, and adhesion molecules necessary for neutrophil tissue
penetration, were examined, together with inflammatory endothelial coagulant
responses. Pretreatment effects on isolated blood neutrophil inflammatory responses
were similarly noted. Mechanistic insight was obtained through assessment of the
temporal response of nuclear factor-kB and its association with heat shock protein
72(HSP72) expression.
Results: Four-hour pretreatment markedly reduced inflammatory endothelial release
of interleukin 8 (2587 6 82 pg/mL control vs 208 6 3 pg/mL u-3 pretreated, P ,
.01) and endothelial expression of intercellular adhesion molecule 1 (196.1 6 2.0
vs 71.9 6 0.6 mean channel fluorescence, P , .01) in response to endotoxin and tu-
mor necrosis factor a. Neutrophil activation (CD11b and respiratory burst) was main-
tained, but pretreated neutrophils had shorter survival. Endothelial inflammatory
stimulation produced rapid increase in nuclear activity of nuclear factor-kB, which
was attenuated by 43% with u-3 pretreatment (P , .01). This coincided with 3-fold
increase (P 5 .03) in protective HSP72 expression with pretreatment.
Conclusion: Acute pre-treatment with a clinically acceptable u-3 infusion atten-
uates perioperative endothelial-neutrophil activation through transcription-level
interaction.
T
he systemic inflammatory response and ischemia–reperfusion have at their
core the common pathogenesis of tissue injury caused by excessive leuko-
cyte–endothelial inflammatory activation and interaction.1-5 Cardiac surgery
generates a prominent systemic inflammatory response2,4-7 and necessitates a period
of cardiac and pulmonary ischemia–reperfusion injury. Pediatric cardiac surgery is
further complicated by the need in many cases for a period of circulatory arrest or
low-flow cardiopulmonary bypass in which multiorgan ischemia–reperfusion injury
occurs. Leukocyte–endothelial interaction is an evolutionary response that minimizes
injury by containing it locally, with some inadvertent normal tissue damage, to
prevent systemic complications. In cardiac surgery, because of the systemic activation
of the endothelium in multiple organ capillary beds, inadvertent and inappropriate
sequestration of leukocytes occurs in multiple organs, producing multiple organ
dysfunction syndrome.2,3,5,8,11
The four main components of the endothelial response to inflammatory activation
are as follows: production of proinflammatory cytokines to recruit neutrophils and
amplify the inflammatory response, upregulation of cell adhesion molecules to allow
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HSP 5 heat shock protein
ICAM-1 5 intercellular adhesion molecule 1
IL 5 interleukin
LPS 5 lipopolysaccharide
mcf 5 mean channel fluorescence
NF-kB 5 nuclear factor kB
TNF-a 5 tumor necrosis factor a
leukocyte adherence and transmigration, generation of a pro-
coagulant environment at the endothelial level, and vasomo-
tor dysfunction.2,3,7 To date, most potential strategies
targeted against the central process of leukocyte–endothelial
activation have focused on inhibiting a single aspect of this
response, such as oligosaccharide antagonists or monoclonal
antibodies against the adhesion molecules on the endothe-
lium or leukocytes,3,10,12,13 antioxidants to counter neutro-
phil attack,5 steroids to prevent neutrophil activation,5 or
leukofiltration.3,5
Pure forms of u-3 fatty acids have been shown to inhibit
inflammation-induced expression of leukocyte adhesion
molecules on the endothelium.14,15 This study examined
whether a clinically acceptable form of u-3 fatty acids that
could be used prophylactically in the setting of cardiac sur-
gery might produce a similar effect in vitro on cell adhesion
molecule expression, as well as the effect on neutrophil-
recruiting cytokines, endothelial procoagulant response, and
neutrophil inflammatory responses, and whether this effect
would arise through a preconditioning type of mechanism.
Materials and Methods
Ethical approval for the study was granted by the Mater Misericor-
diae University Hospital, with written informed consent obtained
from 75 patients undergoing coronary bypass surgery to use any
remnant saphenous vein for endothelial cell isolation.9 Young
healthy volunteers consented to donate a peripheral blood sample
for neutrophil isolation.
Endothelial Cell and Neutrophil Isolation
Endothelial cells were isolated from the remnant saphenous vein
as described previously.16 Medium containing endothelial cell
growth factor (neural bovine extract endothelial cell growth factor;
Sigma-Aldrich, St. Louis, MO, USA) at a concentration of 8 mg/100
mL was added. Cells were grown to the fourth passage for experi-
ments, and endothelial purity was confirmed by greater than 95%
staining with von Willebrand factor (Dako North America, Inc.,
Carpinteria, CA, USA). The cells used in experiments therefore
had not been exposed to any medicinal products or to high blood
glucose levels (as in patients with diabetes), minimizing potential
confounding variables.
Neutrophils were isolated from peripheral blood samples imme-
diately by dextran (Sigma-Aldrich) density sedimentation and Ficoll
(Amersham plc, Little Chalfont, UK) gradient centrifugation, as136 The Journal of Thoracic and Cardiovascular Surgery c Juldescribed previously.17 The neutrophils were suspended in com-
plete medium: Roswell Park Memorial Institute medium containing
10% volume/volume fetal calf serum, 1% volume/volume penicil-
lin–streptomycin solution (GIBCO; Life Technologies Ltd, Paisley,
UK), and placed as aliquots into polypropylene tubes (Sarstedt,
Numbrecht, Germany). These techniques minimize activation of
neutrophils as assessed by size versus granularity dot plots and yield
neutrophil purity greater than 95% according to CD15/CD16
staining on flow cytometry.
Model of Systemic Inflammatory Activation
Endothelial cells were transferred to 12-well plates for experiments,
with 13 105 cells/well in a confluent monolayer. Neutrophils were
used immediately suspended at 2 3 106 cells/mL medium in
polypropylene tubes (Starstedt). Normal medium or medium con-
taining a 1:400 dilution of the parenteral nutrition formulation of
u-3 infusion (Omegaven; Fresenius Kabi AG, Bad Homburg, Ger-
many) was added to each well or tube for 4 hours, the minimum
period of required exposure noted in previous experiments with iso-
lated macrophages.18 After 4 hours, the medium was removed and 1
mL medium containing lipopolysaccharide (LPS) at 1 mg/mL
(Sigma-Aldrich), tumor necrosis factor a (TNF-a) at 0.03 mg/mL
(RnD, UK), or complement component C5a at 0.1 mg/mL (EMD
Chemicals, Inc., San Diego, CA, USA) was added.
Cell Adhesion Molecule Expression
Flow cytometry was used to measure changes in adhesion molecule
expression, with appropriate isotypic controls. Endothelial E-selec-
tin (CD62E) and intercellular adhesion molecule 1 (ICAM-1,
CD54), and neutrophil CD11b/CD18 were assessed with mouse
antihuman R-Phycoerythrin–conjugated monoclonal antibodies
(BD Bioscience, UK). Receptor density on the cell surface was
expressed as mean channel fluorescence (mcf) intensity of the cells.
Endothelial Coagulant Changes
Endothelial surface thrombomodulin levels were assessed with flow
cytometry with a primary mouse antihuman thrombomodulin mono-
clonal antibody (CD141; American Diagnostica Inc, Greenwich,
Conn), and a secondary fluorescein isothiocyanate–conjugated
sheep antimouse IgG (Bioquote Limited, North Yorkshire, UK). Su-
pernatant thrombomodulin and tissue factor levels were measured
with the Imubind thrombomodulin and tissue factor enzyme-linked
immunosorbent assay kits (American Diagnostica).
Proinflammatory Cytokine Release
Supernatants from the endothelial and neutrophil experiments were
used to measure release of the proinflammatory cytokines interleu-
kin (IL) 6, IL-8, and TNF-a with enzyme-linked immunosorbent
assay kits (RnD).
Neutrophil Respiratory Burst
Intracellular reactive oxygen intermediate generation by neutrophils
was assessed with the Orpegen BurstTest Kit (BDBecton Dickinson
UK Limited, Oxford, UK). Briefly, neutrophils stimulated with
phorbol 12-myristate 13-acetate were exposed to dihydrorhodamine
123 to label reactive species for visualization with flow cytometry,
and intensity was expressed as mcf.y 2008
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PEndothelial Cell and Neutrophil Apoptosis and
Viability
Flow cytometric measurements of dual staining with annexin V and
propidium iodide were used to assess the percentage of cells that
were apoptotic or viable (TACS Apoptosis Detection Kit; RnD).
For neutrophils, because of ongoing apoptosis and short lifespan,
exposure to LPS at 1 mg/mL (Sigma-Aldrich) and complement com-
ponent C5a at 0.1 mg/mL (Calbiochem) for 20 hours was necessary
to be able to detect the normal prolongation of neutrophil survival
that occurs with inflammation and consequently assess the effect
of u-3 pretreatment.
Endothelial Nuclear Factor kB and Heat Shock
Protein 72 Expressions
The relative concentrations of the two active subunits of the acute
inflammatory transcription factor nuclear factor-kB (NF-kB), ie
P65 and P50, were measured in endothelial cytoplasmic and nuclear
proteins at different points with the TransAM NF-kB Chemi Kit
(Active Motif, Rixensart, Belgium). Cytoplasmic and nuclear pro-
teins were isolated with a nuclear extract kit (Active Motif), protein
concentrations were equalized with the Bradford assay (Sigma-
Aldrich), and samples were placed in wells coated with an oligonu-
cleotide containing the NF-kB consensus binding site that would be
present in the 50 promoter region of the inflammatory genes acti-
vated by NF-kB. A sandwich enzyme-linked immunosorbent assay
technique was then used to detect p65 or p50 binding to this site.
Results are expressed as relative luminescence units. Heat shock
protein (HSP) 72 levels in the cytoplasmic protein extracts were as-
sessed with Western blotting with samples at the same points as the
NF-kB experiments for comparison of results. The primary antibody
was a mouse antihuman HSP72 monoclonal antibody (SPA-810;
Bioquote), and the secondary was a horseradish peroxidase–conju-
gated goat antimouse IgG1 (DAKO). The relative densitometric
readings for each blot were normalized with b-actin (antihuman
beta actin antibody; Oncogene Research Products, Merck).
Statistical Analysis
Results are expressed as mean 6 SEM. Data were analyzed with a
1-way analysis of variance, with post hoc comparisons performed
with the Bonferroni comparison of means as appropriate.
Results
Endothelial Effects of u-3 Pretreatment
Pretreatment for 4 hours with the u-3 infusion markedly
attenuated release of the potent neutrophil-recruiting cyto-
kine IL-8 and the proinflammatory cytokine IL-6 after 3
hours of inflammatory stimulation with LPS or TNF-
a (Figure 1). Pretreatment also prevented upregulation of
molecules for neutrophil adhesion on the endothelial surface,
both E-selectin for neutrophil rolling on the endothelium and
ICAM-1 for firm neutrophil adherence and degranulation
(Figure 2). Although absolute levels of adhesion molecules
were not measured, but rather changes in mcf were used,
the lack of any change in mcf with u-3 pretreatment indicates
that the endothelium behaves as if it were unstimulated by
TNF or LPS. The endothelial procoagulant response to
inflammation is normally characterized by a reduction inThe Journal of Thothe endothelial surface anticoagulant thrombomodulin and
an increase in procoagulant tissue factor release by the endo-
thelium.2,7 Endothelial surface thrombomodulin levels were
noted to be reduced with inflammatory stimulation with
LPS (57.3 6 0.7 mcf control vs 49.9 6 0.3 mcf LPS stimu-
lation) but were maintained at baseline levels if the endothe-
liumwas pretreated withu-3 fatty acids (64.96 4.9 mcf, P,
.01). Supernatant thrombomodulin levels at the same point
showed no changes in thrombomodulin levels with LPS stim-
ulation (0.2026 0.004 ng/mL vs baseline 0.2076 0.007 ng/
mL, P 5 .8), so the observed reduction in thrombomodulin
levels on the inflammation-activated endothelial surface
likely represents reduced expression, rather than shedding
of the thrombomodulin. Supernatant tissue factor levels
were undetectable.
Endothelial Viability and Reversibility
It was important to confirm that the reduction in endothelial
inflammatory response that occurred with u-3 pretreatment
was not due simply to a reduction in endothelial viability.
Pretreatment with a 1:400 dilution of the u-3 infusion for
4 hours had no significant effect on endothelial viability rel-
ative to untreated cells (Table 1). A time course experiment
with ICAM-1 upregulation in response to LPS stimulation
as the end point was used to assess whether the anti-
inflammatory effects of u-3 pretreatment were reversible.
Endothelial monolayers were pretreated with the u-3 infu-
sion for 4 hours and then exposed to LPS either immediately
or at a delayed interval, and ICAM-1 was measured. Endo-
thelial responsiveness to LPS stimulation returned between
18 to 24 hours after pretreatment (Figure 3).
Effects of u-3 pretreatment on Neutrophil Acute
Inflammatory Responses
Pretreatment with the u-3 infusion did not attenuate the neu-
trophil’s ability to generate reactive oxygen species, express
the endothelial adhesion molecule CD11b/CD18, or release
IL-8 in response to inflammatory stimulation. Neutrophils
have a half-life in the circulation of 6 hours because of an
ongoing process of apoptosis; this ensures that any potential
damaging response is short-lived.19 During cardiac surgery,
this normal rate of apoptosis is reduced, increasing the neu-
trophil’s lifespan not only in the circulation but also poten-
tially within the tissues and thus prolonging the period of
inadvertent tissue damage.19 Stimulation of isolated neutro-
phils with LPS and C5a for 20 hours increased neutrophil sur-
vival as a result of reduced apoptosis, as expected.
Pretreatment with a 1:400 dilution of the u-3 infusion for
4 hours maintained nearly normal neutrophil survival
(Figure 4).
Mechanism of Endothelial Anti-inflammatory Effects
Changes in both the p50 and p65 active subunits of the acute
inflammatory transcription factor NF-kB showed the sameracic and Cardiovascular Surgery c Volume 136, Number 1 137
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lated with tumor necrosis factor
a (TNFa) or endotoxin (LPS) for 3 hours,
and supernatant interleukin 6 (IL-6) and
8 (IL-8) levels were measured. Pretreat-
ment (Omega3) markedly suppressed
interleukin 6 and 8 release relative to
no pretreatment (P < .01 in all cases).pattern, with a 13-fold increase in nuclear levels of the p65
subunit of NF-kB on LPS stimulation that was markedly
attenuated with u-3 pretreatment to 57% of the control
LPS-stimulated levels (P, .01; Figure 5). Endothelial cyto-
plasmic HSP72 levels were assessed at the same points used
in the NF-kB assessments. After 4 hours of pretreatment,
a significant 3-fold increase in HSP72 levels was noted in
the u-3–pretreated group (307% 6 60% vs control 100%,
P5 .03). After 30 minutes of exposure to LPS, there was lit-
tle detectable HSP72 in the u-3–pretreated group but 7-fold
Figure 2. Endothelial cells were stimulated with tumor necrosis
factor a (TNFa) or endotoxin (LPS) for 3 hours, and cell surface
levels of E-selectin (for neutrophil rolling on endothelium) and in-
tercellular adhesion molecule 1 (ICAM-1, for neutrophil firm adhe-
sion on the endothelium) were measured. Pretreatment (Omega3)
prevented upregulation of neutrophil adhesion molecules on
endothelium (P < .01 for all comparisons).138 The Journal of Thoracic and Cardiovascular Surgery c Julyhigher levels in the control group when both were expressed
as a percentage of the control 4-hour pretreatment levels
(31% 6 19% in the u-3–pretreated group vs 244% 6 75%
in the control group, P 5 .05; Figure 6).
Discussion
The link between organ dysfunction and leukosequestration
in cardiac surgery is well established. This study illustrates
that pretreatment with a clinically acceptable u-3 infusion
can attenuate endothelial release of the neutrophil-recruiting
cytokine IL-8 and expression of neutrophil adhesion mole-
cules on the endothelial surface, which may minimize
inappropriate perioperative leukocyte penetration of organs.
This u-3 pretreatment also attempts to preserve the normal
endothelial anticoagulant state through prevention of inflam-
mation-induced reduction in endothelial surface anticoagu-
lant thrombomodulin expression, which may improve
postoperative organ perfusion. Pretreatment does not
interfere with important neutrophil bactericidal functions of
reactive oxygen species generation and CD11b/CD18 ex-
pression. Pretreatment effects on neutrophil adhesion mole-
cule expression by the endothelium appear to be reversible
within 24 hours. These pretreatment effects appear to be me-
diated at transcription level through attenuated activation of
the acute inflammatory transcription factor NF-kB. Effects
on NF-kB activation have a temporal correlation with
HSP72 expression, suggesting a preconditioning type of at-
tenuation of inflammatory NF-kB activation.
TABLE 1. Endothelial cell populations with and without
u-3 fatty pretreatment
Control u-3 Pretreatment P value
Viable 87% 6 1% 80% 6 1% .5
Early apoptotic 8% 6 1% 11% 6 1% .8
Necrotic or late apoptotic 5% 6 1% 9% 6 3% .6
Endothelial cells were exposed to medium containing a 1:400 dilution of the
u-3 infusion or medium only for 4 hours. Percentages of cells that were
viable, were in early apoptosis, or were necrotic or in late apoptosis were
assessed.2008
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PNeutrophils possess some of the most toxic proteases and
reactive oxygen species in the body, making them efficient at
destroying invading pathogens and damaged nonfunctional
tissue.20 They lack, however, the ability to differentiate be-
tween foreign and host antigens, depending on the localized
upregulation of adhesion molecules at a site of infection or
Figure 3. Endothelial cells were exposed to medium only or me-
dium containing 1:400 dilution of u-3 infusion for 4 hours. Subse-
quently, they were stimulated with endotoxin (LPS) immediately
or after a period of exposure to medium only (delayed exposure),
and intercellular adhesion molecule 1 (ICAM-1) levels were
measured. Normal inflammatory upregulation of intercellular
adhesion molecule 1 returned, 18 to 24 hours after u-3 pre-
treatment. All levels are compared to baseline unstimulated
endothelial cells (*).
Figure 4. Neutrophils were stimulated with endotoxin (LPS) and
complement C5a for 20 hours and assessment of viability or apo-
ptosis. Pretreatment prevented inflammation-induced increase
in viability through maintenance of baseline apoptosis levels.The Journal of Thoinjury to guide them to the appropriate area. Once they
have entered the tissues, the release of their stored toxins is
not cell specific, and surrounding normal tissue is inadver-
tently destroyed in the process, although because this is
a localized response, collateral injury is minimized.20 After
cardiac surgery, however, the large number of circulating
inflammatory mediators, or multiorgan ischemia–reperfusion
in the case of circulatory arrest or low-flow bypass, unfortu-
nately means that multiorgan endothelial activation oc-
curs.2,3,5 This converts a localized protective response into
Figure 5. Relative levels of p65 subunit of nuclear factor kB
(NFkB) in nucleus after pretreatment of endothelial cells with me-
dium only or medium containing 1:400 dilution of u-3 infusion
(Omega-3) and subsequent inflammatory stimulation with endo-
toxin (LPS) containing medium for 30 minutes. Pretreatment atten-
uated nuclear factor kB activation. RLU, Relative luminescence
units.
Figure 6. Endothelial cytoplasmic heat shock protein 72 (HSP72)
levels were assessed by Western blotting with their associated
b-actin (B-actin) levels. There was significant upregulation of
HSP72 after 4 hours of pretreatment with 1:400 dilution of u-3 in-
fusion (Omega-3). Opposite trend occurred after 30 minutes of ex-
posure to endotoxin (LPS), with higher heat shock protein 72
levels in control group, suggesting more injury and activation of
control endothelium.racic and Cardiovascular Surgery c Volume 136, Number 1 139
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minimal preoperative organ reserve function can lead to
organ dysfunction or failure.
Pure forms of u-3 fatty acids are known to suppress
inflammation-induced expression of leukocyte adhesion
molecules on the endothelium14,15 and IL-6 and IL-8 produc-
tion by the activated endothelium,14 leading in turn to a reduc-
tion in endothelial transmigration of leukocytes as assessed
by intravital microscopy.15 This study demonstrates that
a clinically acceptable parenteral nutrition formulation of
u-3 infusion can replicate these effects with only 4 hours
of pretreatment. This protection is reversible, likely lasting
only 18 to 24 hours, which reduces the potential for any
adverse side effects.
The inflammation-activated endothelium develops into
a procoagulant phenotype, presumably to contain any infec-
tion, tissue injury, or neutrophil-mediated tissue destruction
locally and to minimize the endothelial inflammatory leakage
by inducing small areas of microcirculatory thrombosis.21
The process is normally localized to a specific site through
control mediated by changes in the localized endothelium
from a normal anticoagulant surface, provided in part by
thrombomodulin expression, to a procoagulant surface, aided
by tissue factor production by the endothelium.2,7,23 Again, in
cardiac surgery, the fact that inflammatory activation of the
endothelium occurs in multiple organ capillary beds leads to
a normally protective inflammatory response’s conversion
to a pathologic response, with diffuse downregulation of
endothelial surface thrombomodulin and diffuse upregulation
of endothelial tissue factor and platelet-activating factor pro-
duction.22 In this study, the normal decrease in cell surface
thrombomodulin that occurs with LPS stimulation of the
endothelium was prevented by pretreatment with the u-3
infusion, which appears to downregulate endothelial surface
expression. Clearly, u-3 pretreatment may have a beneficial
effect in improving organ perfusion by preventing the no-
reflow phenomenon both through maintaining endothelial
surface anticoagulation in the microcirculation and through
inhibiting leukocyte adherence and obstructing accumulation.
This study also illustrates that although pretreatment with
the u-3 infusion has marked anti-inflammatory effects on the
endothelium, neutrophil function is largely preserved.
Pretreatment with the u-3 infusion did not affect respiratory
burst by the neutrophil, CD11b expression, or proinflamma-
tory cytokine production. Interestingly, the only aspect of
neutrophil function that was altered with u-3 pretreatment
was inflammation-induced prolongation of neutrophil
survival, which was markedly attenuated as a result of main-
tenance of near basal levels of apoptosis with pretreatment.
This effect would be beneficial in cardiac surgery because
it would reduce the survival of postoperatively primed
neutrophils while maintaining critical bactericidal functions.
Previous studies with oral supplementation with eicosapen-
taenoic and docosahexaenoic acid for 4 weeks have reported140 The Journal of Thoracic and Cardiovascular Surgery c Juno effect on neutrophil cytokine production or adhesion mol-
ecule expression.24 These findings are consistent with ours
with respect to neutrophil apoptosis, with demonstration in
the neutrophil-like differentiated HL-60 cell line that pre-
treatment with pure u-3 fatty acids increases apoptosis.25
Many of the inflammatory stimuli that activate endothelial
cells—including endotoxin (LPS), complement, reactive
oxygen species, and proinflammatory cytokines such as IL-
1b, TNF-a, and IL-6—converge on the transcription factor
NF-kBwithin the cytoplasm and activate it, leading to upregu-
lation of the key endothelial inflammatory response genes:
genes for adhesion molecules (E-selectin, ICAM-1), genes
for procoagulants (tissue factor, plasminogen activator), and
genes for proinflammatory factors (TNF-a, IL-8, IL-6, IL-1b,
cyclooxygenase 2).22,26 This finding underlies the central
role for NF-kB in the systemic inflammatory response and
ischemia–reperfusion injury. Because of its critical role, it is
important that NF-kB is maintained in an inactive state within
the endothelial cytoplasm, which is achieved by binding of an-
other subunit to theNF-kBp65-p50 dimer, inhibitory kB.5,22,26
In this study, pretreatment with a 1:400 dilution of the u-3
infusion was capable of significantly attenuating an LPS-
stimulated rise in nuclear levels of the active NF-kB subunits,
suggesting inhibition at transcription level. Previous studies
have shown inhibition of NF-kB by oxidized u-3 eicosapen-
taenoic acid15 and unoxidized docosahexaenoic acid14 within
the endothelium. Additionally, pretreatment with this clini-
cally acceptable u-3 infusion has been shown in isolated
murine macrophages to attenuate proinflammatory cytokine
production associated with inhibition of NF-kB.18 Our find-
ing of a temporal association between the 3-fold increase in
HSP72 levels in the cytoplasm after 4 hours of pretreatment
and the subsequent reduction in NF-kB activation is interest-
ing. It may suggest a role for HSP72 in preventing NF-kB
activation within the cytoplasm. This phenomenon has also
been observed in vivo; LPS pretreatment upregulates
HSP72 in rats, which produces smaller myocardial infarcts
in association with lower levels of NF-kB activation within
the heart.27 This may be a direct effect of HSP72 through
its molecular chaperoning functions maintaining NF-kB
inactive.28 In our study, we also noted that although the u-
3 infusion produced an increase in cytoplasmic HSP72 rela-
tive to control levels, after 30 minutes of LPS stimulation
there were actually reduced HSP72 levels in the u-3 group
and 7-fold higher levels in the control group. These findings
are easily explained by the fact that HSP70 accumulation can
also be used as a biomarker of cellular injury and can reach
higher cytoplasmic levels within minutes after physiologic
stress.29 The temporal alignment of HSP72 expression with
u-3 pretreatment and the subsequent attenuation of NF-kB
translocation suggest induction of preconditioning within
the endothelium to attenuate its inflammatory activation.
The u-3 infusion likely also acts through other mediators,
such as the resolvins and protectins.ly 2008
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PIn adult cardiac surgery, there has been a 30% increase in
predicted operative risk during the last decade.30 As the age
of patients referred for cardiac surgery increases, and the in-
cidence of conditions such as diabetes that produce occult
end-organ damage increases in the population in general,
the patients now being considered for surgery have more lim-
ited physiologic reserves within their organ systems. In pedi-
atric cardiac surgery, newborn children with vulnerable
developing organ systems undergo complex procedures
with prolonged bypass times and often circulatory arrest or
low-flow bypass. Challenging both these patient groups
with cardiac surgical systemic inflammatory response and
ischemia–reperfusion injury can create dramatic increases
in postoperative multiple organ dysfunction or even organ
failure. Pretreatment with a clinically acceptableu-3 infusion
for only 4 hours attenuated one of the major pathogenic re-
sponses underlying this injury, and this treatment deserves
further investigation in a cardiopulmonary bypass and circu-
latory arrest model as a clinical strategy to improve outcome
in our high-risk patient population.
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